GILD AI Stock Analysis – Buy, Hold, or Avoid?
Gilead Sciences, Inc. (GILD)
Fundamentals
Gilead Sciences displays solid financial fundamentals with consistent revenue growth and improving profitability metrics, underscored by healthy margins and strong cash generation. Despite a volatile earnings history earlier, recent quarters show stable EPS beats and signs of operational resilience in its core biopharmaceutical business. The stock is supported by a strong market position in antiviral therapies with steady R&D investment fueling potential future pipeline growth.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
4.39% YoY
Q1 2026
Net Income
53.69% YoY
Q1 2026
Net Margin
Q1 2026
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q1 2026
Net Income Growth YoY
Latest Quarter: Q1 2026
Revenue Per Share Growth YoY
Latest Quarter: Q1 2026
EPS Growth YoY
Latest Quarter: Q1 2026
Book Value Per Share Growth YoY
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.0B | 7.9B | 7.8B | 7.1B | 6.7B | 7.6B | 7.5B | 7.0B |
| Revenue Growth YoY | +4.39% | +4.69% | +2.97% | +1.84% | -0.28% | +6.40% | +7.02% | +5.36% |
| Net Income | 2.0B | 2.2B | 3.1B | 2.0B | 1.3B | 1.8B | 1.3B | 1.6B |
| Net Income Growth YoY | +53.69% | +22.43% | +143.58% | +21.44% | +131.53% | +24.77% | -42.52% | +54.45% |
| EPS | $1.63 | $1.76 | $2.46 | $1.57 | $1.06 | $1.43 | $1.00 | $1.29 |
| EPS Growth YoY | +53.77% | +23.08% | +146.00% | +21.71% | +131.74% | +24.35% | -42.86% | +53.57% |
Profitability Metrics
Technical Analysis
Gilead Sciences (GILD) is currently in a technical consolidation phase with mixed signals across major indicators. The stock is in a Stage 3 topping phase with range-bound momentum and is trading near critical support levels, showing signs of potential breakout or pullback. Key moving averages and chart patterns indicate cautious optimism but require confirmation on price action above resistance to signal a stronger uptrend.
No extreme reading
Mixed signals
Range-bound market
Watching for cross
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Gilead Sciences displays solid financial fundamentals with consistent revenue growth and improving profitability metrics, underscored by healthy margins and strong cash generation. Despite a volatile earnings history earlier, recent quarters show stable EPS beats and signs of operational resilience in its core biopharmaceutical business. The stock is supported by a strong market position in antiviral therapies with steady R&D investment fueling potential future pipeline growth.
Latest Earnings
Q1 2026 Earnings (Mar 31, 2026)
Earnings Per Share (EPS)
Actual
$2.03
Estimated
$1.91
Surprise
+$0.12
Surprise %
+6.28%
Revenue
Actual
$6.96B
Estimated
$6.91B
Surprise
+$46.62M
Surprise %
+0.67%
Historical Earnings
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $2.03 | $1.86 | $2.47 | $2.01 | $1.81 | $1.90 | $2.02 | $2.01 |
| EPS (Estimated) | $1.91 | $1.81 | $2.13 | $1.96 | $1.78 | $1.74 | $1.53 | $1.61 |
| EPS Surprise | +$0.12 | +$0.05 | +$0.34 | +$0.05 | +$0.03 | +$0.16 | +$0.49 | +$0.40 |
| % Diff | +6.3% | +2.8% | +16.0% | +2.6% | +1.7% | +9.2% | +32.0% | +24.8% |
| Revenue | ||||||||
| Revenue (Actual) | $6.96B | $7.93B | $7.77B | $7.08B | $6.67B | $7.57B | $7.55B | $6.95B |
| Revenue (Estimated) | $6.91B | $7.69B | $7.45B | $6.98B | $6.81B | $7.15B | $7.02B | $6.7B |
| Revenue Surprise | +$46.62M | +$234.64M | +$323.62M | +$99.5M | -$143.87M | +$416.55M | +$529.36M | +$246.47M |
| % Diff | +0.7% | +3.1% | +4.3% | +1.4% | -2.1% | +5.8% | +7.5% | +3.7% |
Valuation
Gilead Sciences (GILD) presents a fundamentally solid profile with strong profitability and cash flow metrics, supported by robust margins and healthy balance sheet ratios. Valuation metrics indicate that the stock is trading at a reasonable level compared to peers and its historical multiples, with analysts broadly optimistic about upside potential, reflecting a moderate buy consensus. Technically, the stock displays mixed signals but maintains key support levels, while sentiment remains cautiously positive amid limited recent news flow and balanced institutional interest.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 21.38 | 17.43 | 11.28 | 17.65 | 26.43 | 16.15 | 20.96 | 13.30 |
| Price to Sales | 24.87 | 19.24 | 17.76 | 19.49 | 20.94 | 15.23 | 13.86 | 12.31 |
| Price to Book | 7.36 | 6.71 | 6.41 | 7.02 | 7.29 | 5.96 | 5.66 | 4.68 |
| Enterprise Value to EBITDA | 61.72 | 56.12 | 33.95 | 46.78 | 60.13 | 42.65 | 65.16 | 35.58 |
| Enterprise Value to Revenue | 26.96 | 21.39 | 20.03 | 22.29 | 23.49 | 17.52 | 16.27 | 15.27 |
Sentiment & Analyst Ratings
Overall sentiment on Gilead Sciences (GILD) is moderately positive, supported by strong analyst buy ratings and optimism around its diverse pipeline and recent acquisitions. While the stock is trading below analyst average price targets, indicating perceived value, cautiousness remains due to insider selling and mixed price target revisions. Recent news highlights robust financial performance and promising drug developments that underpin investor confidence.
Analyst Recommendations
Risk Assessment
Gilead Sciences exhibits a moderately strong liquidity position with improving current and quick ratios, supporting their ability to meet short-term obligations despite significant acquisition-related charges impacting earnings in 2026. The company carries moderate leverage, with a manageable debt load and strong interest coverage, but faces heightened financial and execution risks from large acquisition spend and competitive pressures in cell therapy and oncology segments. Regulatory uncertainties and ongoing litigation contribute additional risk factors, tempering the investment outlook despite solid revenue growth in core HIV products.
Liquidity & Solvency
Frequently Asked Questions about GILD
AI Answers: Common Questions About GILD
Get AI-powered answers to the questions investors ask most about Gilead Sciences, Inc.
Yes, Gilead is a good buy based on strong fundamentals, fair valuation with a forward P/E of ~17.5x, and consistent earnings growth. The stock offers stable margins near 79% gross and 37% operating, with positive pipeline developments supporting growth.
No immediate sell signal. Technicals suggest short-term consolidation, but fundamentals and sentiment support holding or buying. Consider selling only if the stock breaks below key support levels near $127 or if negative regulatory or earnings surprises occur.
Key risks include patent cliffs, competitive biosimilars, acquisition integration challenges, regulatory and litigation pressures, and pricing/reimbursement changes affecting profitability.
Upside price targets range from $133 to $136 near-term resistance, with longer-term targets near $140.61 and the 52-week high of $157.29, supported by pipeline and earnings growth.
Gilead is fairly valued with a forward P/E around 17.5x, EV/EBITDA near 12.5x, and a price-to-sales ratio just over 5. These multiples reflect steady earnings growth and quality cash flow generation.
The company shows steady revenue growth of 4-5% annually, strong gross margins (~79%), improving operating margins (~37%), and EPS growth from losses in 2024 to $6.84 in 2025. Cash flow and margin sustainability are robust.
Technically, GILD is consolidating with neutral momentum indicators, a death cross present, and an ascending triangle pattern forming. Confirmation of a breakout above $133 is needed for a bullish trend; support lies near $127 and $114.
Upcoming catalysts include Q2 2026 earnings on August 4, FDA applications for HIV drugs, CHMP recommendation for Trodelvy, and integration progress from acquisitions like Arcellx and Ouro Medicines.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.